Skip to main navigation
Repare Therapeutics
  • Company
    • About Us
    • Leadership
    • Partnering
    • Contact
  • Science
    • Discovery Platform
    • Therapeutic Focus
    • Scientific References
  • Pipeline
    • Development Pipeline
    • Camonsertib ATR Inhibitor
    • Lunresertib PKMYT1 Inhibitor
    • Polθ Inhibitor
  • Clinical Trials
    • Clinical Trials Overview
  • Careers
    • Job Opportunities
    • Our Culture
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
      • Entity report pursuant to Bill S-211
    • Investor Resources
      • Investor FAQs
      • Investor Email Alerts
      • PFIC Statement
      • Contact IR
Select Page

Press Releases

Press Releases

Jul 15, 2025
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
May 13, 2025
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
May 01, 2025
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
Apr 25, 2025
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
Mar 31, 2025
Repare Therapeutics Announces Leadership Transitions
Mar 07, 2025
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 03, 2025
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Jan 09, 2025
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
Media & IR Contact
Investor Relations & Media Contact

Steve Forte
Contact Us

Helpful Tools
  • Print Page
  • Email Alerts
  • RSS Feeds
Company
  • About Us
  • Leadership
  • Partnering
  • Contact
Science
  • Discovery Platform
  • Therapeutic Focus
  • Scientific References
Pipeline
  • Development Pipeline
  • Camonsertib ATR Inhibitor
  • Lunresertib PKMYT1 Inhibitor
  • Polθ Inhibitor
Clinical Trials
  • Clinical Trials Overview
Careers
  • Job Opportunities
  • Our Culture
Investors & Media
  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investor Resources
Repare Therapeutics logo
© 2025 Repare Therapeutics
  • Privacy Policy
  • Terms of Use
  • Cookie Policy